[go: up one dir, main page]

AU2002227052A1 - Treatments for neurogenetic disorders, impulse control disorders, and wound healing - Google Patents

Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Info

Publication number
AU2002227052A1
AU2002227052A1 AU2002227052A AU2705202A AU2002227052A1 AU 2002227052 A1 AU2002227052 A1 AU 2002227052A1 AU 2002227052 A AU2002227052 A AU 2002227052A AU 2705202 A AU2705202 A AU 2705202A AU 2002227052 A1 AU2002227052 A1 AU 2002227052A1
Authority
AU
Australia
Prior art keywords
disorders
wound healing
treatments
neurogenetic
impulse control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002227052A
Inventor
Daniel John Driscoll
Mary Catherine Lessig
Nathan Andrew Shapira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of AU2002227052A1 publication Critical patent/AU2002227052A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The subject invention provides methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising topiramate. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury.
AU2002227052A 2000-11-30 2001-11-30 Treatments for neurogenetic disorders, impulse control disorders, and wound healing Abandoned AU2002227052A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25011300P 2000-11-30 2000-11-30
US60/250,113 2000-11-30
PCT/US2001/044923 WO2002043731A2 (en) 2000-11-30 2001-11-30 Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Publications (1)

Publication Number Publication Date
AU2002227052A1 true AU2002227052A1 (en) 2002-06-11

Family

ID=22946345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002227052A Abandoned AU2002227052A1 (en) 2000-11-30 2001-11-30 Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Country Status (7)

Country Link
US (3) US20020082222A1 (en)
EP (1) EP1345602B1 (en)
AT (1) ATE474572T1 (en)
AU (1) AU2002227052A1 (en)
CA (1) CA2430010A1 (en)
DE (1) DE60142632D1 (en)
WO (1) WO2002043731A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043731A2 (en) * 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US6462084B1 (en) * 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
AU2003239455A1 (en) * 2002-05-14 2003-12-02 Ralph Ryback Method for treating dermatoses and tissue damage
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US20080131501A1 (en) * 2006-12-04 2008-06-05 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
EP2306899B1 (en) 2008-06-12 2014-08-13 Amygdala Pty Ltd Detection of hypokinetic and/or hyperkinetic states
CN102256602A (en) * 2008-10-21 2011-11-23 诺沃德米克斯国际有限公司 Compositions for treating epithelial tissue
KR20120092175A (en) 2009-12-04 2012-08-20 죤 이. 그랜트 Treating impulse control disorders with catechol-o- methyl-transferase inhibitors
TWI570472B (en) * 2011-10-03 2017-02-11 三菱瓦斯化學股份有限公司 Aromatic polycarbonate polarized lens
TWI474831B (en) 2012-09-14 2015-03-01 Univ Taipei Medical Use of immunomodulatory protein in promotion of wound healing or treatment of tissue injury
EP2961319A4 (en) * 2013-03-01 2016-10-19 Global Kinetics Corp Pty Ltd SYSTEM AND METHOD FOR EVALUATING PULSE CONTROL DISORDER
EP3113684B1 (en) 2014-03-03 2020-07-01 Global Kinetics Pty Ltd System for assessing motion symptoms
IL256912B2 (en) * 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
US20230248627A1 (en) * 2020-06-26 2023-08-10 Universidade Do Minho Composition for hair follicle modulation, methods and uses thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US892088A (en) 1907-09-26 1908-06-30 William Rich Marine fire-indicating system and extinguisher.
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5571521A (en) * 1984-01-16 1996-11-05 Lasker; Sigmund E. Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition
US5856245A (en) * 1988-03-14 1999-01-05 Nextec Applications, Inc. Articles of barrier webs
US5632727A (en) * 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
GB9102660D0 (en) * 1991-02-07 1991-03-27 Ultra Lab Ltd Wound dressing materials
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5692302A (en) * 1991-03-01 1997-12-02 Warner-Lambert Company Razor cartridges comprising wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5614561A (en) * 1991-03-01 1997-03-25 Warner-Lambert Company Antihistamine-wound healing compositions and methods for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5662924A (en) * 1991-03-21 1997-09-02 Smith & Nephew Plc Wound dressing
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
DK0612232T3 (en) * 1991-11-06 1999-11-08 Bioderm Inc Closing wound dressing and applicator
US5376376A (en) * 1992-01-13 1994-12-27 Li; Shu-Tung Resorbable vascular wound dressings
USRE36370E (en) * 1992-01-13 1999-11-02 Li; Shu-Tung Resorbable vascular wound dressings
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
WO1993020837A1 (en) * 1992-04-21 1993-10-28 Ajinomoto Co., Inc. Remedy for wound
JPH07508975A (en) * 1992-04-23 1995-10-05 バーレックス　ラボラトリーズ　インコーポレイテッド Bioadhesive aqueous mineral oil emulsion ointment base, topical pharmaceutical compositions comprising it and its use in wound healing
GB9212303D0 (en) * 1992-06-10 1992-07-22 Johnson & Johnson Medical Ltd Absorbent products
GB2272645B8 (en) * 1992-11-23 2010-02-10 Johnson & Johnson Medical Wound dressing
GB9225581D0 (en) * 1992-12-08 1993-01-27 Courtaulds Plc Wound dressings
US5902600A (en) * 1992-12-21 1999-05-11 Healthpoint, Ltd. Hydrogel polymer wound dressing
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
GB2275685B (en) * 1993-03-03 1997-04-30 Johnson & Johnson Medical Water soluble wound dressing materials
GB2275686B (en) * 1993-03-03 1997-04-30 Johnson & Johnson Medical Swellable wound dressing materials
US5960795A (en) * 1993-07-16 1999-10-05 Tecnol Medical Products, Inc. Wound covering device
ES2168312T3 (en) * 1993-09-24 2002-06-16 Univ Southern California USE OF ANGIOTENSIN III AND ITS ANALOGS FOR TISSULAR REPAIR.
CA2172494A1 (en) * 1993-09-24 1995-03-30 Kathleen Elizabeth Rodgers Use of angiotensin ii analogs in tissue repair
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US5603946A (en) * 1993-10-08 1997-02-18 Bristol-Myers Squibb Company Wound dressing
US5498629A (en) * 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5507775A (en) * 1994-01-21 1996-04-16 Progressive Surgical Products Inc. Tissue expansion and approximation device
ATE241340T1 (en) * 1994-02-17 2003-06-15 New York Blood Ct Inc BIOLOGICAL BIOADHESIVE PREPARATIONS CONTAINING FIBRIN ADHESIVES AND LIPOSOMES, METHOD FOR THEIR PRODUCTION AND USE
ATE241394T1 (en) * 1994-04-08 2003-06-15 Atrix Lab Inc ASSOCIATED POLYMER SYSTEM FOR USE WITH A MEDICAL DEVICE
US5522794A (en) * 1994-06-16 1996-06-04 Hercules Incorporated Method of treating human wounds
US5685834A (en) * 1994-07-29 1997-11-11 Barth; Alan H. Surgical dressing material
US5512041A (en) * 1994-10-07 1996-04-30 Scott Health Care Wound dressing for promoting moist wound healing
US5519020A (en) * 1994-10-28 1996-05-21 The University Of Akron Polymeric wound healing accelerators
US5998692A (en) * 1995-01-26 1999-12-07 Innovative Technologies Limited Wound dressing
EP0805663B1 (en) * 1995-01-27 2000-08-02 Coloplast A/S A dressing having a three-dimensional part and processes for the preparation of such a dressing
US5876743A (en) * 1995-03-21 1999-03-02 Den-Mat Corporation Biocompatible adhesion in tissue repair
US5578022A (en) * 1995-04-12 1996-11-26 Scherson; Daniel A. Oxygen producing bandage and method
US5690795A (en) 1995-06-05 1997-11-25 Applied Materials, Inc. Screwless shield assembly for vacuum processing chambers
US5834432A (en) * 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
CA2224253A1 (en) * 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
US6087549A (en) * 1997-09-22 2000-07-11 Argentum International Multilayer laminate wound dressing
KR970027051A (en) * 1995-11-02 1997-06-24 조규향 Novel Sulfamate Compounds Containing Carbamoyl Groups
US5892088A (en) * 1995-11-02 1999-04-06 Yukong Limited Sulfamate compound containing N-substituted carbamoyl group and method for preparing the same
GB9523253D0 (en) * 1995-11-14 1996-01-17 Mediscus Prod Ltd Portable wound treatment apparatus
WO1997041899A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5968001A (en) * 1996-05-14 1999-10-19 Bristol-Myers Squibb Company Wound dressings with leak prevention seal
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
SK284305B6 (en) * 1996-06-28 2005-01-03 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
SK284266B6 (en) * 1996-06-28 2004-12-01 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives used in treating psoriasis
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
US6033684A (en) * 1996-08-28 2000-03-07 Jonor, Inc. Compositions and methods for wound management
US5807300A (en) * 1996-09-20 1998-09-15 Nix, Jr.; Frank H. Holder for wound dressing
US5897516A (en) * 1996-09-27 1999-04-27 Bristol-Myers Squibb Company Method of treating a wound by monitoring the swelling of a hydrocolloid layer in a wound dressing
DK0932400T3 (en) * 1996-10-08 2003-02-10 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in the treatment of neuropathic pain
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
US5807341A (en) * 1996-12-11 1998-09-15 Team Medical Llc Medical catheter dressing device
US5977428A (en) * 1996-12-20 1999-11-02 Procyte Corporation Absorbent hydrogel particles and use thereof in wound dressings
US5780048A (en) * 1997-03-20 1998-07-14 Lee; Chung Chih First aid bandage dressing system and method of application thereof
US5972332A (en) * 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
US5760006A (en) * 1997-06-23 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis
US6136341A (en) * 1998-02-27 2000-10-24 Petito; George D. Collagen containing tissue adhesive
US5989577A (en) * 1998-03-02 1999-11-23 Children's Hospital Medical Center Nontoxic vernix compositions and method of producing
WO2000000130A1 (en) 1998-06-29 2000-01-06 The Procter & Gamble Company Liquid transport member for high flux rates against gravity
WO2000010610A2 (en) 1998-08-19 2000-03-02 Theramark Limited Drug targeting
WO2000023059A2 (en) * 1998-10-20 2000-04-27 Ortho-Mcneil Pharmaceutical, Inc. Use of anticonvulsant derivatives for treating alcohol dependency
ATE261724T1 (en) * 1998-11-17 2004-04-15 Ortho Mcneil Pharm Inc ANTICONVULSIVE DERIVATIVES FOR THE TREATMENT OF POST-TRAAUMATIC STRESS DISEASES
BR0007897A (en) 1999-02-01 2001-10-30 Ortho Mcneil Pharm Inc Use of anticonvulsant derivatives to treat bulimia nervosa
MY129238A (en) * 1999-02-17 2007-03-30 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in treating essential tremor
WO2000050020A2 (en) * 1999-02-24 2000-08-31 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
CA2369095C (en) * 1999-04-08 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
PT1187603E (en) * 1999-06-14 2007-11-16 Vivus Inc '' ASSOCIATION THERAPY TO PROMOTE WEIGHT LOSS AND THE TREATMENT OF OBESITY ''
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002043731A2 (en) 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
AU2003239455A1 (en) * 2002-05-14 2003-12-02 Ralph Ryback Method for treating dermatoses and tissue damage

Also Published As

Publication number Publication date
EP1345602B1 (en) 2010-07-21
EP1345602A2 (en) 2003-09-24
US8084491B2 (en) 2011-12-27
WO2002043731B1 (en) 2003-04-03
ATE474572T1 (en) 2010-08-15
WO2002043731A3 (en) 2003-02-20
US20050101543A1 (en) 2005-05-12
US20020082222A1 (en) 2002-06-27
CA2430010A1 (en) 2002-06-06
US20080021094A1 (en) 2008-01-24
WO2002043731A2 (en) 2002-06-06
DE60142632D1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
AU2002227052A1 (en) Treatments for neurogenetic disorders, impulse control disorders, and wound healing
IL139231A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract
BRPI9908182B8 (en) wound healing matrix protein compositions
WO2001001932A3 (en) Oligosaccharide aldonic acids and their topical use
AU2003301190A1 (en) Administration of capsaicinoids
WO2000044367A3 (en) A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
WO2005034883A3 (en) A method of healing skin wounds in mammals and a composition therefor
WO2000040227A3 (en) Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2003073981A3 (en) Novel of cytokine inhibitors
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
WO1999043344A3 (en) Matrix protein compositions for wound healing
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2002009639A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2002011743B1 (en) Treatment of prostate cancer
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2001087343A3 (en) Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
BR0212576A (en) Method for the treatment of skin disorders
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
CA2441461A1 (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
WO2001008671A3 (en) Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses
WO2006068778A3 (en) The use of plant extracts to prevent and/or reduce the signs of subjective discomfort and/or irritation in the topical application of cosmetic products